Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Vistusertib + WEHI-539 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vistusertib | AZD2014|AZD-2014 | mTOR Inhibitor 51 | Vistusertib (AZD2014) is an ATP-competitive inhibitor of mTOR, which may result in tumor growth inhibition (PMID: 23375793, PMID: 31707687). | |
WEHI-539 | BCL-XL inhibitor 14 | WEHI-539 is a selective inhibitor of BCL-XL that stimulates apoptotic responses in cells, resulting in killing of tumor cells (PMID: 23603658, PMID: 32752193). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA act mut | breast cancer | predicted - sensitive | Vistusertib + WEHI-539 | Preclinical - Cell culture | Actionable | In a preclinical study, the ATP-competitive mTORC1/2 inhibitor Vistusertib (AZD2014) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663). | 27974663 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|